On January 13, 2022, Aadi Bioscience, Inc. (the "Company") entered into that certain Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the "Agreement") with Fresenius Kabi, LLC pursuant to which Fresenius Kabi will manufacture Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound), for intravenous use ("Fyarro") for the Company, and the Company will purchase Fyarro as a finished drug product from Fresenius Kabi, on a purchase-order basis. In addition to manufacturing, Fresenius Kabi will perform specified labeling, packaging and serialization activities in respect of Fyarro for the benefit of the Company.